Cholinesterase inhibitor use does not significantly influence the ability of123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 10, 2007, Pages 1069-1071

  Taylor, John Paul ^a,d   Colloby, Sean J ^a   McKeith, Ian G ^a   Burn, David J ^a   Williams, David ^b   Patterson, Jim ^c   O'Brien, John T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 FLUOROPHENYL) N (1 IODOPROP 1 EN 3 YL)TROPANE I 123; ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE TRANSPORTER; RADIOISOTOPE; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DOPAMINE UPTAKE; DRUG ANTAGONISM; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SEX DIFFERENCE; BINDING SITE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; METABOLISM; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ALZHEIMER DISEASE; BINDING SITES; CAUDATE NUCLEUS; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MALE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 34848902028     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.111666     Document Type: Article

References (17)

1. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40.
2. O'Brien JT, Colloby S, FenwickJ, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25.
3. Tsukada H, Nishiyama S, Ohba H, et al. Cholinergic neuronal modulations affect striatal dopamine transporter activity: PET studies in the conscious monkey brain. Synapse 2001;42:193-5.
4. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-68.
5. Villares JC, Stavale JN. Age-related changes in the N-methyl-aspartate receptor binding sites within the human basal ganglia. Exp Neurol 2001;171 :391-404.
6. Kilbourn MR, Kemmerer ES, Desmond TJ, et al. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain. Exp Neurol 2004;188:387-90.
7. Knol RJJ, de Bruin CM, Booij J. Is the [123I]FP-CIT binding to striatal dopamine transporters influenced by acetylcholinesterase inhibitors? Eur J Nucl Med Mol Imaging 2006;33:S211.
8. Farde L, Ginovart N, Halldin C, et al. A PET study of [11C][beta]-CIT-FE binding to the dopamine transporter in the monkey and human brain. Int J Neuropsychopharmacol 2000;3:203-14.
9. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
10. Patel A, Uhl G, Kuhar MJ. Species differences in dopamine transporters: postmortem changes and glycosylation differences. J Neurochem 1993;61 :496-500.
11. Lee SH, Rhee J, Koh JK, et al. Species differences in functions of dopamine transporter: paucity of MPP+ uptake and cocaine binding in bovine dopamine transporter. Neurosci Lett 1996;214:199-201.
12. Suzuki M, Desmond TJ, Albin RL, et al. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 2002;51:767-71.
13. Erixon-Lindroth N, Farde L, Robins Wahlin T-B, et al. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res Neuroimaging 2005;138:1-12.
14. Li S, Kim KY, Kim JH, et al. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in rat midbrain. Neurosci Lett 2004;363:29-32.
15. Padilla S, Marshall RS, Hunter DL, et al. Neurochemical effects of chronic dietary and repeated high-level acute exposure to chlorpyrifos in rats. Toxicol Sci 2005;88:161-71.
16. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology2003;28:413- 20.
17. de Win MM, Habraken JB, Reneman L, et al. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005;30:996-1005.